Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 312
Selected: 0
NCT IDTitle
NCT07081646A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT00122330Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT06830798Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT00867932Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02013037The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
NCT03397888The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
NCT05501717Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT02372513National Lysosomal Acid Lipase Deficiency Study
NCT03574506Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series
NCT01371825Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
NCT02090179Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT00312039Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT00040157Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
NCT01895127Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
NCT04933682Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT03053102Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01567085Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
NCT00401947A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
NCT04256148ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
NCT03075904A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
NCT02245867Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
NCT03369236A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT06312644Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06079372Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT01194804E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT05840055ACT with NMOSD Patients and Caregivers Pilot Study
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04609696Study of the Metabolism of Danicopan in Healthy Adults
NCT02605993Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT04999020Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
NCT04021082CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
NCT05428696Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants
NCT01997229Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
NCT05876351Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
NCT06374264Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
NCT02376751An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
NCT05109390A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT05234567A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT01399593Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
NCT02614898Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT05778071Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05780645A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants
NCT05319912A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT05641311Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
NCT04320602Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab